BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 36.40
+0.40 (1.11%)
At close: Mar 6, 2026
BioGend Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 222.34 | 167.65 | 109.91 | 31.45 | 9.27 | Upgrade
|
| Revenue Growth (YoY) | 32.62% | 52.53% | 249.51% | 239.26% | 565.40% | Upgrade
|
| Cost of Revenue | 62.18 | 37.14 | 20.29 | 8.67 | 6.21 | Upgrade
|
| Gross Profit | 160.16 | 130.51 | 89.62 | 22.78 | 3.06 | Upgrade
|
| Selling, General & Admin | 145.41 | 124.04 | 95.16 | 75.73 | 54.09 | Upgrade
|
| Research & Development | 124.45 | 128.72 | 171 | 166.27 | 113.27 | Upgrade
|
| Operating Expenses | 270.65 | 252.77 | 266.16 | 241.99 | 167.37 | Upgrade
|
| Operating Income | -110.5 | -122.26 | -176.54 | -219.21 | -164.31 | Upgrade
|
| Interest Expense | -0.15 | -0.22 | -0.26 | -0.09 | -0.02 | Upgrade
|
| Interest & Investment Income | 8.04 | 6.07 | 6.92 | 4.59 | 2.88 | Upgrade
|
| Earnings From Equity Investments | -1.84 | -2.46 | -0.84 | - | -11.35 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | 0.03 | 0.07 | 0.51 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.84 | 0.62 | 1.46 | 0.74 | 0.87 | Upgrade
|
| EBT Excluding Unusual Items | -103.61 | -118.25 | -169.22 | -213.9 | -171.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -10 | - | - | 26.7 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.44 | Upgrade
|
| Pretax Income | -103.61 | -128.25 | -169.22 | -213.9 | -144.27 | Upgrade
|
| Income Tax Expense | -8.31 | -8.31 | -8.3 | -8.4 | - | Upgrade
|
| Earnings From Continuing Operations | -95.3 | -119.94 | -160.92 | -205.5 | -144.27 | Upgrade
|
| Minority Interest in Earnings | 10.69 | 3.47 | 4.59 | 21.04 | 5.78 | Upgrade
|
| Net Income | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 | Upgrade
|
| Net Income to Common | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 123 | 120 | 103 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 123 | 120 | 103 | 101 | Upgrade
|
| Shares Change (YoY) | -0.37% | 2.32% | 16.69% | 1.77% | 15.90% | Upgrade
|
| EPS (Basic) | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 | Upgrade
|
| EPS (Diluted) | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 | Upgrade
|
| Free Cash Flow | -65.52 | -99.56 | -164.76 | -186.96 | -137.47 | Upgrade
|
| Free Cash Flow Per Share | -0.53 | -0.81 | -1.37 | -1.81 | -1.36 | Upgrade
|
| Gross Margin | 72.03% | 77.85% | 81.54% | 72.44% | 33.00% | Upgrade
|
| Operating Margin | -49.70% | -72.93% | -160.63% | -697.11% | -1772.67% | Upgrade
|
| Profit Margin | -38.05% | -69.47% | -142.23% | -586.58% | -1494.07% | Upgrade
|
| Free Cash Flow Margin | -29.47% | -59.38% | -149.91% | -594.54% | -1483.13% | Upgrade
|
| EBITDA | -60.73 | -74.76 | -125.21 | -170.87 | -137.9 | Upgrade
|
| EBITDA Margin | -27.31% | -44.59% | -113.92% | - | - | Upgrade
|
| D&A For EBITDA | 49.77 | 47.5 | 51.33 | 48.35 | 26.41 | Upgrade
|
| EBIT | -110.5 | -122.26 | -176.54 | -219.21 | -164.31 | Upgrade
|
| EBIT Margin | -49.70% | -72.93% | -160.63% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.